Dr. Katz’s investigates the sequelae of obesity and type 2 diabetes mellitus in youth. Her research involves the intersection of sleep, obesity, and glucose intolerance and prevention of cardiovascular risk. Her studies have led to the evaluation of quantitative tools important for assessment of metabolic risk in youth.
Dr. McCormack investigates the intersection of neuroendocrinology and metabolism. Her translational research program involves two areas. The first involves studying those with genetic disorders, including primary mitochondrial diseases and Friedreich's ataxia, with characterized risk for diabetes mellitus. Second, Dr. McCormack focuses on brain disorders associated with excess weight gain, including brain tumor-related hypothalamic obesity syndrome and idiopathic intracranial hypertension.
Dr. Rubenstein's research focuses on basic and translational studies of novel means to improve outcomes in cystic fibrosis. He initially focused on correcting the dysfunction of mutant cystic fibrosis transmembrane conductance regulator (CFTR) proteins, which led him to study how molecular chaperones regulate the biogenesis and trafficking of CFTR and other proteins that are relevant to cystic fibrosis.
Many research projects aim to keep things on track, from healthcare expenditures to patients’ long-term health. Make certain that you know of the research happenings this week at The Children’s Hospital of Philadelphia by reading on for more highlights.
When children with multiple swollen joints come to the Center for Childhood Arthritis and Rheumatic Disease for treatment, and then a few weeks later they are back on the field playing sports, their energy is contagious for pediatric rheumatologist Pamela Weiss, MD MSCE.
Our team is working on a study to better understand neurological problems, including seizures and developmental delays, that occur in children with hyperinsulinism, including HI/HA syndrome, and type 1 diabetes mellitus.
The goal of this study is to investigate the efficacy and safety of Canagliflozin (which is experimental) in children and adolescents ages 10 to 18 years old with Type 2 diabetes and poor control (i.e., an HbA1c of 6.5% to 10.5%).
The McCormack Lab studies the intersection of neuroendocrinology and metabolism, with two areas of focus. First, the lab studies genetic disorders with increased risk for diabetes mellitus, including mitochondrial diseases. Second, investigators in the lab focus on brain tumor-related hypothalamic obesity syndrome.